KCM
CYTK icon

Kingdon Capital Management’s Cytokinetics CYTK Stock Holding History

Kingdon Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.4M Buy
+157,100
New +$11.3M 1.37% 27
2024
Q4 		– Sell
-266,700
Closed -$14.1M – 82
2024
Q3 		$14.1M Hold
266,700
– – 1.56% 20
2024
Q2 		$14.4M Buy
266,700
+150,700
+130% +$9.1M 1.55% 21
2024
Q1 		$8.13M Buy
+116,000
New +$8.97M 0.89% 57

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kingdon Capital Management's CYTK Position: Q2 2026 in Review

Kingdon Capital Management opened a new position in Cytokinetics (CYTK) in Q2 2026: 157,100 shares worth $13.4M. The stake represents 1.37% of the portfolio and ranks #27 among its holdings. This is a return to the name: Kingdon Capital Management previously reported a position in CYTK as recently as Q3 2024.

Kingdon Capital Management first reported a position in CYTK in Q1 2024 and has held it in 4 quarters since. The position peaked at $14.4M in Q2 2024. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Kingdon Capital Management held 157,100 shares of Cytokinetics worth $13.4M as of Q2 2026.
  • Cytokinetics was a new Kingdon Capital Management position in Q2 2026.
  • Cytokinetics made up 1.37% of Kingdon Capital Management's portfolio in Q2 2026, its #27 holding.
  • Kingdon Capital Management first reported a position in Cytokinetics in Q1 2024 and has held it in 4 quarters since.
  • Kingdon Capital Management's Cytokinetics position peaked at $14.4M in Q2 2024.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Kingdon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.